Here are 1-3 brief analogies for Odyssey Therapeutics (ODTX):

• Vertex Pharmaceuticals for autoimmune diseases. (Similar focus on precision small-molecule therapies for complex conditions, but in the immunology space rather than genetic diseases).

• A Denali Therapeutics for inflammatory and autoimmune conditions. (Emphasizes a scientifically-driven drug discovery engine tackling complex diseases with novel approaches, but in immunology instead of neuroscience).

• OD-001: An oral small-molecule RIPK2 inhibitor that has achieved proof-of-concept in a Phase 2a trial for ulcerative colitis.
• OD-002: An oral small-molecule SLC15A4 inhibitor currently in IND-enabling studies for inflammatory and autoimmune diseases.
• Treg-specific TNFR2 agonist: A wholly owned preclinical program designed to modulate regulatory T cells.
• TSLP and IL-33 bispecific antagonist: A wholly owned preclinical program targeting two key inflammatory cytokines.
• IRAK4 scaffolding inhibitor: A wholly owned preclinical program targeting the IRAK4 signaling pathway.
• IRF5 inhibitor: A preclinical program, in collaboration with Terray Therapeutics, targeting interferon regulatory factor 5.

As a clinical-stage biopharmaceutical company, Odyssey Therapeutics (ODTX) is primarily focused on the research, development, and clinical testing of new drug candidates for autoimmune and inflammatory diseases. The company does not currently have any approved commercial products on the market and, therefore, does not have major customers in the traditional sense of companies or individuals purchasing its products or services.

Once its drug candidates, such as OD-001 and OD-002, receive regulatory approval, the ultimate beneficiaries of Odyssey Therapeutics' work would be patients suffering from conditions like inflammatory bowel disease (IBD), systemic lupus erythematosus (SLE), and other autoimmune and inflammatory disorders. However, these patients would receive treatments through healthcare providers (e.g., hospitals, pharmacies, clinics) rather than directly purchasing from Odyssey Therapeutics.

Gary D. Glick, Ph.D.

Founder, President & Chief Executive Officer

Dr. Glick is a chemist and serial biotechnology entrepreneur who founded Odyssey Therapeutics in 2021. He has an extensive track record, having founded several successful companies. Notably, he founded IFM Therapeutics, where he served as CEO and oversaw the progression of three programs into clinical development and executed major transactions, including the sale of oncology assets to Bristol-Myers Squibb for over $2.3 billion and an NLRP3 inhibitor program to Novartis for $1.6 billion. Prior to Odyssey, he co-founded and launched Scorpion Therapeutics in 2020, which grew to nearly 50 employees and raised $270 million across two financings, and was later acquired by Eli Lilly and Company for up to $2.5 billion. Earlier in his career, Dr. Glick also founded Lycera Corporation and FirstWave Bio. His career demonstrates a pattern of founding and leading biotech companies that have attracted significant investment and achieved successful acquisitions.

Jason Haas, MBA

Chief Financial Officer

Mr. Haas brings over two decades of experience in financial leadership and strategic growth to Odyssey Therapeutics. Before joining Odyssey, he served as Chief Financial Officer at Syros Pharmaceuticals, Inc. Prior to his CFO role, Mr. Haas held senior investment banking positions, including Co-Head of Americas, Healthcare Investment Banking at Barclays plc and Head of Americas, Healthcare Investment Banking at Deutsche Bank AG. He also served as a Managing Director on the Healthcare Investment Banking team at Goldman Sachs & Co. His extensive experience in investment banking, capital markets, and biopharma includes involvement in deal sourcing, evaluation, and execution, which often includes working with private equity-backed companies.

Natalie Dales, Ph.D.

Chief of Research Operations and Portfolio Strategy

Dr. Dales is an accomplished scientist with over 20 years of small molecule drug discovery experience. Before her promotion to Chief of Research Operations and Portfolio Strategy at Odyssey, she served as the company's Executive Vice President of Enabling Sciences. Prior to joining Odyssey, Dr. Dales was an Executive Director of Global Discovery Chemistry at Novartis, where she also led Portfolio and Strategy and served as a Senior Advisor for the Novartis Genesis Labs, an internal innovation incubator. She also worked on oncology, cardiovascular, and metabolism programs at Millennium Pharmaceuticals.

Dennis Dean, Ph.D.

Executive Vice President, Head of Nonclinical Development

Dr. Dean is a seasoned drug development leader with over 25 years of experience in both biotechnology and large pharmaceutical companies. Before joining Odyssey, he served as Chief Nonclinical Development Officer at Third Harmonic Bio. Previously, he was Chief Development Officer at IFM Therapeutics, where he advanced multiple programs into clinical trials and contributed to three successful acquisitions. Prior to IFM, Dr. Dean was Senior Vice President and Head of Preclinical and Exploratory Development at Vertex Pharmaceuticals, where he led translational functions including DMPK, preclinical safety assessment, clinical pharmacology, biomarkers, and modeling and simulation.

Jeffrey Hermes, Ph.D.

Executive Vice President of Enabling Sciences

Dr. Hermes is a seasoned professional with over 30 years of experience in biochemistry, pharmacology, and in vitro sciences within the biopharmaceutical industry. Most recently, he served as the Vice President of In Vitro Pharmacology at Kallyope, where he led efforts in in vitro pharmacology, screening, and enzymology to develop small molecule therapeutics. Earlier in his career, Dr. Hermes held positions of increasing responsibility at Roche and Merck.

Key Risks to Odyssey Therapeutics (ODTX)

1. Clinical Development and Regulatory Approval Risk: Odyssey Therapeutics is a clinical-stage biopharmaceutical company, and its success is highly dependent on the successful outcome of its clinical trials and subsequent regulatory approvals for its product candidates, particularly OD-001 and OD-002. Biopharmaceutical product development is an inherently long, costly, and uncertain process with a high risk of failure. Factors such as unforeseen safety issues, lack of efficacy in larger trials, or inability to meet regulatory requirements could significantly delay or prevent the commercialization of their drug candidates. The company's lead program, OD-001, has achieved proof-of-concept in a Phase 2a trial, and OD-002 is in IND-enabling studies, meaning significant further clinical and regulatory hurdles remain.
2. Competition Risk: The autoimmune and inflammatory disease markets, which Odyssey Therapeutics targets, are highly competitive. The company faces competition from established pharmaceutical companies and other biotechnology firms that may have greater financial resources, more experienced development teams, or more advanced product candidates. The success of Odyssey's programs depends on its ability to develop therapies that are more effective, safer, or more convenient than existing or future treatments in the market.
3. Financial Risk and Dependence on Future Funding: As a clinical-stage company, Odyssey Therapeutics has an accumulated deficit and currently generates no revenue from product sales, with past revenue coming solely from collaboration agreements. The company incurs significant research and development expenses and will require substantial additional funding to complete the development of its product candidates and prepare for commercialization. While the company recently completed an initial public offering (IPO), there is a risk that it may not be able to secure sufficient additional capital in the future on favorable terms, or at all, which could hinder its ability to advance its pipeline.

Addressable Market Sizes for Odyssey Therapeutics' Main Products

OD-001 (targeting Ulcerative Colitis and Inflammatory Bowel Disease)

• Ulcerative Colitis (UC) Treatment Market:
  • Global: The market size was valued at approximately USD 7.96 billion in 2024 and is projected to grow to USD 13.79 billion by 2035.
  • U.S.: The market size in the U.S. was approximately USD 4.8 billion in 2024.
• Inflammatory Bowel Disease (IBD) Treatment Market (includes Ulcerative Colitis):
  • Global: The market size was valued at USD 26.6 billion in 2024 and is anticipated to reach USD 47.3 billion by 2034.
  • U.S.: The market size in the U.S. was approximately USD 16.6 billion in 2024.

OD-002 (targeting Systemic Lupus Erythematosus and Interferonopathies)

• Systemic Lupus Erythematosus (SLE) Treatment Market:
  • Global: The market size was valued at USD 2.85 billion in 2024 and is expected to reach USD 4.44 billion by 2032.
  • North America: This region held the largest share of the global systemic lupus erythematosus market, accounting for 39.4% in 2023.
• Interferonopathies (addressed within the broader Interferon Market, which includes autoimmune diseases):
  • Global: The global Interferon market size was valued at approximately USD 9.74 billion in 2024 and is projected to reach USD 14.14 billion by 2034.
  • North America: This region led the Interferon market in 2024, with a revenue of approximately USD 3.78 billion.

For Odyssey Therapeutics (ODTX), a clinical-stage biopharmaceutical company focused on autoimmune and inflammatory diseases, future revenue growth over the next 2-3 years is expected to be driven primarily by key pipeline advancements and strategic collaborations.

1. Advancement of OD-001 for Ulcerative Colitis: Odyssey's lead asset, OD-001, an oral RIPK2 inhibitor, has achieved proof-of-concept in a Phase 2a trial for ulcerative colitis. The company plans to conduct additional mid-stage studies, both as a monotherapy and in combination with Takeda's Entyvio. Successful progression through these clinical stages and achievement of significant development milestones in the next 2-3 years could lead to milestone payments from potential partners or strengthen the company's position for future commercialization deals.
2. Progression of OD-002 into Clinical Development: OD-002, an oral SLC15A4 inhibitor, is currently in IND-enabling studies with a targeted Phase 1/2a start outside the U.S. in 2027. Advancing this program into human clinical trials for systemic lupus erythematosus (SLE) and interferonopathies would represent a significant validation of its potential and could attract collaboration and licensing revenue.
3. Formation of New Strategic Collaborations and Partnerships: Odyssey's strategy includes executing on existing and pursuing additional collaborations. Securing new licensing agreements or development partnerships for its promising preclinical and early-stage clinical assets, such as the TNFR2 agonist (OD-003) or the bispecific TSLP/IL-33 antagonist (OD-004), could provide upfront payments, research funding, and milestone payments, thereby directly contributing to revenue growth.
4. Pipeline Expansion through Early-Stage Asset Progression: The company aims to enable a new clinical entry every 12-18 months from its early-stage pipeline. The advancement of these wholly-owned preclinical programs, including an IRAK4 scaffolding inhibitor, into clinical development would broaden Odyssey's pipeline and create additional opportunities for future partnerships or external funding, which could generate revenue.

Share Issuance

• Odyssey Therapeutics completed an Initial Public Offering (IPO) on May 7, 2026, raising $279 million through the sale of 15.5 million shares at $18.00 per share.
• A concurrent private placement with an affiliate of TPG Life Sciences Innovations generated approximately $25 million by issuing 1.388 million shares, bringing the total gross proceeds from the IPO and private placement to around $304 million.
• Since its incorporation in April 2021 and prior to its IPO, Odyssey Therapeutics had raised an aggregate of approximately $726.5 million from over 30 investors through various private funding rounds.

Inbound Investments

• Prior to going public in May 2026, Odyssey Therapeutics secured approximately $726.5 million in private funding from more than 30 investors since its founding in 2021.
• In conjunction with its IPO, the company received a private placement investment of approximately $25 million from an affiliate of TPG Life Sciences Innovations.

Outbound Investments

• Odyssey Therapeutics's "Investments And Advances," which includes non-current investments in affiliates, real estate, and securities, amounted to $35.20 million as of December 2025.

Capital Expenditures

• Odyssey Therapeutics reported $0.00 million in capital expenditures as of December 2025, for both the quarter and the trailing twelve months.